In lung cancer, based on these important targets and signaling pathways, EGFR, KRAS, ALK, ROS1, RET, BRAF, MET, HER-2, and NTRK inhibitors have been applied, rewriting the era of the treatment of lung cancer. This evidence concerns the gene EGFR and lung cancer.